Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Basharat Ahmad, Aamir Saeed, Melvin A. Castrosanto, Muhammad Amir Zia, Umar Farooq, Zaheer Abbas & Sara Khan. (2023) Identification of natural marine compounds as potential inhibitors of CDK2 using molecular docking and molecular dynamics simulation approach. Journal of Biomolecular Structure and Dynamics 41:17, pages 8506-8516.
Read now
Read now
S.S. Liang, X.G. Liu, Y.X. Cui, S.L. Zhang, Q.G. Zhang & J.Z. Chen. (2021) Molecular mechanism concerning conformational changes of CDK2 mediated by binding of inhibitors using molecular dynamics simulations and principal component analysis. SAR and QSAR in Environmental Research 32:7, pages 573-594.
Read now
Read now
Hanzhi Liang, Jintong Du, Reham M. Elhassan, Xuben Hou & Hao Fang. (2021) Recent progress in development of cyclin-dependent kinase 7 inhibitors for cancer therapy. Expert Opinion on Investigational Drugs 30:1, pages 61-76.
Read now
Read now
Jianzhong Chen, Laixue Pang, Wei Wang, Lifei Wang, John Z. H. Zhang & Tong Zhu. (2020) Decoding molecular mechanism of inhibitor bindings to CDK2 using molecular dynamics simulations and binding free energy calculations. Journal of Biomolecular Structure and Dynamics 38:4, pages 985-996.
Read now
Read now
Qi Zhou. (2017) Targeting Cyclin-Dependent Kinases in Ovarian Cancer. Cancer Investigation 35:6, pages 367-376.
Read now
Read now
Hervé Galons, Nassima Oumata, Olfa Gloulou & Laurent Meijer. (2013) Cyclin-dependent kinase inhibitors closer to market launch?. Expert Opinion on Therapeutic Patents 23:8, pages 945-963.
Read now
Read now
Articles from other publishers (36)
Junying Wang & Guangyu Zhu. (2023) A precise prognostic signature in CTNNB1-mutant hepatocellular carcinoma: Prognosis prediction and precision treatment exploration. Heliyon 9:12, pages e22382.
Crossref
Crossref
Elif Kubat Oktem, Ummuhan Demir, Metin Yazar & Kazim Yalcin Arga. (2023) Three candidate anticancer drugs were repositioned by integrative analysis of the transcriptomes of species with different regenerative abilities after injury. Computational Biology and Chemistry 106, pages 107934.
Crossref
Crossref
Peddaguravagari Mounika, Bannimath Gurupadayya, Honnavalli Yogish Kumar & Bannimath Namitha. (2023) An Overview of CDK Enzyme Inhibitors in Cancer Therapy. Current Cancer Drug Targets 23:8, pages 603-619.
Crossref
Crossref
Kaixuan Zeng, Weihao Li, Yue Wang, Zifei Zhang, Linjie Zhang, Weili Zhang, Yue Xing & Chi Zhou. (2023) Inhibition of CDK1 Overcomes Oxaliplatin Resistance by Regulating ACSL4‐mediated Ferroptosis in Colorectal Cancer. Advanced Science 10:25.
Crossref
Crossref
Iwona Sidorkiewicz, Maciej Jóźwik, Angelika Buczyńska, Anna Erol, Marcin Jóźwik, Marcin Moniuszko, Katarzyna Jarząbek, Magdalena Niemira & Adam Krętowski. (2023) Identification and subsequent validation of transcriptomic signature associated with metabolic status in endometrial cancer. Scientific Reports 13:1.
Crossref
Crossref
Polina Rusina, Erik Gandalipov, Yana Abdusheva, Maria Panova, Alexandra Burdenkova, Vasiliy Chaliy, Maria Brachs, Oleg Stroganov, Ksenia Guzeeva, Igor Svitanko, Alexander Shtil & Fedor Novikov. (2023) Imidazole-4-N-acetamide Derivatives as a Novel Scaffold for Selective Targeting of Cyclin Dependent Kinases. Cancers 15:15, pages 3766.
Crossref
Crossref
Yuanting Li, Minghao Chen, Qing Chen, Min Yuan, Xi Zeng, Yan Zeng, Meibo He, Baiqiang Wang & Bin Han. (2023) Bioinformatics Identification of Therapeutic Gene Targets for Gastric Cancer. Advances in Therapy 40:4, pages 1456-1473.
Crossref
Crossref
Manzoor Ahmad Mir & Umar Y. Mir. 2023. Therapeutic potential of Cell Cycle Kinases in Breast Cancer. Therapeutic potential of Cell Cycle Kinases in Breast Cancer
269
289
.
Wenwu Liu, Yaoguang Huang, Limeng Wu, Wenjie Liu, Xiaowen Jiang, Zihua Xu & Qingchun Zhao. (2022) Novel tacrine derivatives as potential CDK9 inhibitors with low cholinesterase inhibitory properties: design, synthesis, and biological evaluation. New Journal of Chemistry 46:40, pages 19342-19356.
Crossref
Crossref
Zhouling Xie, Shuzeng Hou, Xiaoxiao Yang, Yajun Duan, Jihong Han, Qin Wang & Chenzhong Liao. (2022) Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts. Journal of Medicinal Chemistry 65:9, pages 6356-6389.
Crossref
Crossref
Deendyal Bhurta & Sandip B. Bharate. (2021) Analyzing the scaffold diversity of cyclin‐dependent kinase inhibitors and revisiting the clinical and preclinical pipeline. Medicinal Research Reviews 42:2, pages 654-709.
Crossref
Crossref
LouJin Song, Ramsey Bekdash, Kumi Morikawa, Jose R. Quejada, Alison D. Klein, Danielle Aina-Badejo, Kazushige Yoshida, Hannah E. Yamamoto, Amy Chalan, Risako Yang, Achchhe Patel, Dario Sirabella, Teresa M. Lee, Leroy C. Joseph, Fuun Kawano, Junco S. Warren, Rajesh K. Soni, John P. Morrow & Masayuki Yazawa. (2022) Sigma non-opioid receptor 1 is a potential therapeutic target for long QT syndrome. Nature Cardiovascular Research 1:2, pages 142-156.
Crossref
Crossref
Yi Liu, Leilei Fu, Junhao Wu, Ming Liu, Guan Wang, Bo Liu & Lan Zhang. (2022) Transcriptional cyclin-dependent kinases: Potential drug targets in cancer therapy. European Journal of Medicinal Chemistry 229, pages 114056.
Crossref
Crossref
Özgür Cem Erkin, Betül Cömertpay & Esra Göv. (2022) Integrative Analysis for Identification of Therapeutic Targets and Prognostic Signatures in Non-Small Cell Lung Cancer. Bioinformatics and Biology Insights 16, pages 117793222210887.
Crossref
Crossref
George Sgouros, Wesley E. Bolch, Arturo Chiti, Yuni K. Dewaraja, Dimitris Emfietzoglou, Robert F. Hobbs, Mark Konijnenberg, Katarina Sjögreen-Gleisner, Lidia Strigari, Tzu-Chen Yen & Roger W. Howell. (2022) ICRU REPORT 96, Dosimetry-Guided Radiopharmaceutical Therapy. Journal of the ICRU 21:1, pages 1-212.
Crossref
Crossref
Jiancheng Lv, Ping-an Chang, Xin Li, Xiao Yang, Jie Han, Hao Yu, Zijian Zhou, Haiwei Yang, Pengchao Li, Jiexiu Zhang & Qiang Lu. (2021) Identification of the circRNA-miRNA-mRNA Regulatory Network in Bladder Cancer by Bioinformatics Analysis. International Journal of Genomics 2021, pages 1-22.
Crossref
Crossref
Rosa Wijnen, Camilla Pecoraro, Daniela Carbone, Hamid Fiuji, Amir Avan, Godefridus J. Peters, Elisa Giovannetti & Patrizia Diana. (2021) Cyclin Dependent Kinase-1 (CDK-1) Inhibition as a Novel Therapeutic Strategy against Pancreatic Ductal Adenocarcinoma (PDAC). Cancers 13:17, pages 4389.
Crossref
Crossref
Krzysztof Koras, Ewa Kizling, Dilafruz Juraeva, Eike Staub & Ewa Szczurek. (2021) Interpretable deep recommender system model for prediction of kinase inhibitor efficacy across cancer cell lines. Scientific Reports 11:1.
Crossref
Crossref
Nicholas A. Meanwell & Ramesh Sistla. 2021. Applications of Heterocycles in the Design of Drugs and Agricultural Products. Applications of Heterocycles in the Design of Drugs and Agricultural Products
31
100
.
Hera Saqub, Hannah Proetsch-Gugerbauer, Vladimir Bezrookove, Mehdi Nosrati, Edith M. Vaquero, David de Semir, Ryan J. Ice, Sean McAllister, Liliana Soroceanu, Mohammed Kashani-Sabet, Robert Osorio & Altaf A. Dar. (2020) Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9. Scientific Reports 10:1.
Crossref
Crossref
Polina V. Rusina, Ilya Yu. Titov, Maria V. Panova, Victor S. Stroylov, Yana R. Abdyusheva, Elizaveta Yu. Murlatova, Igor V. Svitanko & Fedor N. Novikov. (2020) Modeling of novel CDK7 inhibitors activity by molecular dynamics and free energy perturbation methods. Mendeleev Communications 30:4, pages 430-432.
Crossref
Crossref
Jianzhong Chen, Xingyu Wang, John Z. H. Zhang & Tong Zhu. (2018) Effect of Substituents in Different Positions of Aminothiazole Hinge-Binding Scaffolds on Inhibitor–CDK2 Association Probed by Interaction Entropy Method. ACS Omega 3:12, pages 18052-18064.
Crossref
Crossref
Xiaoxia Hu, Hui Zhao, Youzhi Wang, Zhan Liu, Bainian Feng & Chunlei Tang. (2018) Synthesis and biological evaluation of novel 5,6-dihydropyrimido[4,5-f]quinazoline derivatives as potent CDK2 inhibitors. Bioorganic & Medicinal Chemistry Letters 28:20, pages 3385-3390.
Crossref
Crossref
Aravind Subramanian, Rajiv Narayan, Steven M. Corsello, David D. Peck, Ted E. Natoli, Xiaodong Lu, Joshua Gould, John F. Davis, Andrew A. Tubelli, Jacob K. Asiedu, David L. Lahr, Jodi E. Hirschman, Zihan Liu, Melanie Donahue, Bina Julian, Mariya Khan, David Wadden, Ian C. Smith, Daniel Lam, Arthur Liberzon, Courtney Toder, Mukta Bagul, Marek Orzechowski, Oana M. Enache, Federica Piccioni, Sarah A. Johnson, Nicholas J. Lyons, Alice H. Berger, Alykhan F. Shamji, Angela N. Brooks, Anita Vrcic, Corey Flynn, Jacqueline Rosains, David Y. Takeda, Roger Hu, Desiree Davison, Justin Lamb, Kristin Ardlie, Larson Hogstrom, Peyton Greenside, Nathanael S. Gray, Paul A. Clemons, Serena Silver, Xiaoyun Wu, Wen-Ning Zhao, Willis Read-Button, Xiaohua Wu, Stephen J. Haggarty, Lucienne V. Ronco, Jesse S. Boehm, Stuart L. Schreiber, John G. Doench, Joshua A. Bittker, David E. Root, Bang Wong & Todd R. Golub. (2017) A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles. Cell 171:6, pages 1437-1452.e17.
Crossref
Crossref
Tinghan Li, Tianwei Weng, Minzan Zuo, Zhihui Wei, Ming Chen & Zhiyu Li. (2016) Recent progress of cyclin-dependent kinase inhibitors as potential anticancer agents. Future Medicinal Chemistry 8:17, pages 2047-2076.
Crossref
Crossref
A.A. Clancy, J.N. Spaans & J.I. Weberpals. (2016) The forgotten woman's cancer: vulvar squamous cell carcinoma (VSCC) and a targeted approach to therapy. Annals of Oncology 27:9, pages 1696-1705.
Crossref
Crossref
Kenji Tamura. (2015) Development of cell-cycle checkpoint therapy for solid tumors. Japanese Journal of Clinical Oncology, pages hyv131.
Crossref
Crossref
Radek Jorda, Eva Schütznerová, Petr Cankař, Veronika Brychtová, Jana Navrátilová & Vladimír Kryštof. (2015) Novel arylazopyrazole inhibitors of cyclin-dependent kinases. Bioorganic & Medicinal Chemistry 23:9, pages 1975-1981.
Crossref
Crossref
Jeannette Calderón-Arancibia, Christian Espinosa-Bustos, Álvaro Cañete-Molina, Ricardo Tapia, Mario Faúndez, Maria Torres, Adam Aguirre, Margot Paulino & Cristian Salas. (2015) Synthesis and Pharmacophore Modelling of 2,6,9-Trisubstituted Purine Derivatives and Their Potential Role as Apoptosis-Inducing Agents in Cancer Cell Lines. Molecules 20:4, pages 6808-6826.
Crossref
Crossref
Jonas Cicenas, Karthik Kalyan, Aleksandras Sorokinas, Asta Jatulyte, Deividas Valiunas, Algirdas Kaupinis & Mindaugas Valius. (2014) Highlights of the Latest Advances in Research on CDK Inhibitors. Cancers 6:4, pages 2224-2242.
Crossref
Crossref
Mathew P. Martin, Sanne H. Olesen, Gunda I. Georg & Ernst Schönbrunn. (2013) Cyclin-Dependent Kinase Inhibitor Dinaciclib Interacts with the Acetyl-Lysine Recognition Site of Bromodomains. ACS Chemical Biology 8:11, pages 2360-2365.
Crossref
Crossref
Ivana Gojo, Mariola Sadowska, Alison Walker, Eric J. Feldman, Swaminathan Padmanabhan Iyer, Maria R. Baer, Edward A. Sausville, Rena G. Lapidus, Da Zhang, Yali Zhu, Ying-Ming Jou, Jennifer Poon, Karen Small & Rajat Bannerji. (2013) Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias. Cancer Chemotherapy and Pharmacology 72:4, pages 897-908.
Crossref
Crossref
Tomáš Gucký, Radek Jorda, Marek Zatloukal, Václav Bazgier, Karel Berka, Eva Řezníčková, Tibor Béres, Miroslav Strnad & Vladimír Kryštof. (2013) A Novel Series of Highly Potent 2,6,9-Trisubstituted Purine Cyclin-Dependent Kinase Inhibitors. Journal of Medicinal Chemistry 56:15, pages 6234-6247.
Crossref
Crossref
Ernst Schonbrunn, Stephane Betzi, Riazul Alam, Mathew P. Martin, Andreas Becker, Huijong Han, Rawle Francis, Ramappa Chakrasali, Sudhakar Jakkaraj, Aslamuzzaman Kazi, Said M. Sebti, Christopher L. Cubitt, Anthony W. Gebhard, Lori A. Hazlehurst, Joseph S. Tash & Gunda I. Georg. (2013) Development of Highly Potent and Selective Diaminothiazole Inhibitors of Cyclin-Dependent Kinases. Journal of Medicinal Chemistry 56:10, pages 3768-3782.
Crossref
Crossref
John J Nemunaitis, Karen A Small, Paul Kirschmeier, Da Zhang, Yali Zhu, Ying-Ming Jou, Paul Statkevich, Siu-Long Yao & Rajat Bannerji. (2013) A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies. Journal of Translational Medicine 11:1, pages 259.
Crossref
Crossref
Yan Li, Weimin Gao, Feng Li, Jinghui Wang, Jingxiao Zhang, Yinfeng Yang, Shuwei Zhang & Ling Yang. (2013) An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors. Molecular BioSystems 9:9, pages 2266.
Crossref
Crossref